Skip to main content

Market Overview

NIH Director Francis Collins To Step Down By Year-End, Dismisses Rumors Linking Resignation And COVID-19 Origins Controversy

Share:
NIH Director Francis Collins To Step Down By Year-End, Dismisses Rumors Linking Resignation And COVID-19 Origins Controversy

National Institutes of Health Director Francis Collins plans to step down by the end of the year, the agency announced Tuesday.

What Happened: Collins has served three decades at the NIH and has headed it for over 12 years. He is the longest-serving presidentially appointed NIH director.

“It has been an incredible privilege to lead this great agency for more than a decade,” said Collins. “I fundamentally believe, however, that no single person should serve in the position too long, and that it’s time to bring in a new scientist to lead the NIH into the future.”

Why It Matters: Collins assumed the role of the NIH Director under President Barack Obama on Aug. 17, 2009. 

The physician-geneticist was involved in the launch of several measures related to the ongoing COVID-19 pandemic including  Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) — a public-private partnership that developed a coordinated research strategy for prioritizing and speeding developments of promising treatments and vaccines.

Anthony Fauci, the director of the National Institute of Allergy and Infectious Diseases (NIAID), tried to talk Collins out of resigning, reported Fox News.

Collins told Fox News that his departure from the role was unrelated to the controversies over the origin of the coronavirus. “People are always looking for some kind of cause and effect here. I want to absolutely assure you and anybody else listening that that had nothing to do with my decision,” said Collins.

At the end of last month, it was reported that NIH is close to concluding trials evaluating a mix n match COVID-19 vaccines regime. The trial involves mixed boosters and initial doses from Pfizer Inc (NYSE: PFE), Moderna Inc (NASDAQ: MRNA), and Johnson & Johnson (NYSE: JNJ), as per Fauci.

Read Next: Pfizer COVID-19 Vaccine Effectiveness Wanes But The Shot Is Good For Keeping People Out Of Hospitals, Says Study

Photo: Courtesy of National Human Genome Research Institute via Wikimedia

 

Related Articles (JNJ + MRNA)

View Comments and Join the Discussion!

Posted-In: Anthony Fauci Covid-19 Francis Collins NIHBiotech Government News General Best of Benzinga

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com